Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Non-Current Assets: 2021-2024

Historic Non-Current Assets for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $313.8 million.

  • Krystal Biotech's Non-Current Assets rose 16.83% to $314.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.4 million, marking a year-over-year increase of 16.83%. This contributed to the annual value of $313.8 million for FY2024, which is 36.17% up from last year.
  • Latest data reveals that Krystal Biotech reported Non-Current Assets of $313.8 million as of FY2024, which was up 36.17% from $230.4 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Non-Current Assets registered a high of $313.8 million during FY2024, and its lowest value of $174.7 million during FY2022.
  • Its 3-year average for Non-Current Assets is $239.6 million, with a median of $230.4 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first decreased by 5.08% in 2022, then surged by 36.17% in 2024.
  • Krystal Biotech's Non-Current Assets (Yearly) stood at $184.0 million in 2021, then fell by 5.08% to $174.7 million in 2022, then skyrocketed by 31.93% to $230.4 million in 2023, then spiked by 36.17% to $313.8 million in 2024.